Diego de Miguel-Perez

13PUBLICATIONS
32CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Venereology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Sep 27, 2025
Correction: Hernández-Pedro et al. Impact of Tyrosine Kinase Inhibitors on the Immune Response to SARS-CoV-2 Vaccination in Patients with Thoracic Malignancies. Vaccines 2023, 11, 1612.

Norma Hernández-Pedro, Marisol Arroyo-Hernández, Pedro Barrios-Bernal

|Nov 19, 2024
Extracellular vesicles containing SARS-CoV-2 proteins are associated with multi-organ dysfunction and worse outcomes in patients with severe COVID-19.

Diego de Miguel-Perez, Marisol Arroyo-Hernandez, Sabrina La Salvia

|Oct 28, 2023
Impact of Tyrosine Kinase Inhibitors on the Immune Response to SARS-CoV-2 Vaccination in Patients with Non-Small Cell Lung Cancer.

Norma Hernández-Pedro, Marisol Arroyo-Hernández, Pedro Barrios-Bernal

|Dec 09, 2022
Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer.

Diego de Miguel-Perez, Alessandro Russo, Muthukumar Gunasekaran

|Nov 10, 2022
Emerging noncoding RNAs contained in extracellular vesicles: rising stars as biomarkers in lung cancer liquid biopsy.

Giuseppe Cammarata, Diego de Miguel-Perez, Alessandro Russo

|Jun 24, 2022
Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question.

Camila Ordóñez-Reyes, Juan Esteban Garcia-Robledo, Diego F Chamorro

Pageof 3

Frequent Collaborators

4 joint publications

Alessandro Russo

2 joint publications

Oscar Arrieta

2 joint publications

Victor A Sosa-Hernandez

2 joint publications

Christian Rolfo